title: Adverse Drug Events-based Tumor Stratification for Ovarian Cancer Patients Receiving Platinum Therapy.
abstract: The underlying molecular mechanisms of adverse drug events (ADEs) associated with cancer therapy drugs may overlap with their antineoplastic mechanisms. In a previous study, we developed an ADE-based tumor stratification framework (known as ADEStrata) with a case study of breast cancer patients receiving aromatase inhibitors, and demonstrated that the prediction of per-patient ADE propensity simultaneously identifies high-risk patients experiencing poor outcomes. In this study, we aim to evaluate the ADEStrata framework with a different tumor type and chemotherapy class - ovarian cancer treated with platinum chemotherapeutic drugs. We identified a cohort of ovarian cancer patients receiving cisplatin (a standard platinum therapy) from The Cancer Genome Atlas (TCGA) (n=156). We demonstrated that somatic variant prioritization guided by known ADEs associated with cisplatin could be used to stratify patients treated with cisplatin and uncover tumor subtypes with different clinical outcomes.
authors: Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
authors: Chen
authors: C
authors: Wang
authors: Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
authors: Michael T
authors: MT
authors: Zimmermann
authors: Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
authors: Christopher G
authors: CG
authors: Chute
authors: Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
authors: Guoqian
authors: G
authors: Jiang